Introduction
Epilepsy is the most common neurologic disorder affecting people of all ages with up to 3% of the population suffering epilepsy at some point in their lives. 1 Temporal lobe epilepsy (TLE) is the most common and most intractable epilepsy syndrome, and as many as 70% of these patients are drug-refractory. 2 Thus, one third of TLE patients continue to experience seizures despite taking antiepileptic drugs (AEDs). 3 Seizures can be harmful to the brain. This is well established for prolonged seizures and status epilepticus in animal models and clinical studies, although it remains unresolved whether spontaneous (i.e. epileptic) seizures cause significant neuron loss. 4 However, the emergence of high-resolution neuroimaging of patients has revealed damage progression in epilepsy patients who continue to experience seizures. 2 As a result, there has been considerable interest in defining the molecular pathways involved in seizure-induced neuronal death. This may have implications for therapeutic strategies not only to mitigate damage and cognitive dysfunction in epilepsy but also influencing epileptogenesis after a brain injury. 5, 6 Research on the mechanism, by which neurons die after status epilepticus, has identified some hallmarks of apoptosis. 5, 6 In particular, upregulation of pro-and anti-apoptotic Bcl-2 family proteins in, both, resected TLE samples and experimental models of seizure-induced neuronal death. 7 The Bcl-2 gene family comprises more than 20 different members that either positively or negatively regulate apoptosis. 8 Bcl-2 family proteins are typically small (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) (30) and are defined according to the presence of one or more homology domains (BH domains). Antiapoptotic members of the Bcl-2 family such as Bcl-2 and Bcl-xl promote mitochondrial function and stabilization via direct actions on mitochondrial membrane integrity, Ca 2+ mobilization, and, perhaps, antioxidant properties. 9 Both pro-and anti-apoptotic Bcl-2 family proteins are also important in regulating endoplasmic reticulum (ER)-based functions including ER-to-mitochondrial Ca 2+ signaling. 10 Mitochondrial dysfunction and apoptosis proceed when a subgroup of proapoptotic Bcl-2 family proteins called BH3-only members is activated, for example by transcriptional activation or post-translational modification. This leads to disabling antiapoptotic members by dimerizing and/or directly activating multidomain Bax/Bak. 8 Brain injury, subsequent to seizures, may result in detectable levels of certain proteins in the cerebrospinal fluid or plasma. In the present study, we aimed to assess the levels of Bcl-2, as a surrogate marker of apoptosis, in the sera of children with TLE and to evaluate the impact of apoptosis on to assess cognitive functions.
Subjects and methods

Subjects
Each local ethical committee of National Research Centre and Ain Shams University approved the study. A legal written consent was obtained from the parents of all cases and controls. This study included 30 children and adolescents with non-lesional TLE (age range 5-15 years). Their diagnosis was based on the criteria of classification of epileptic syndromes according to the Commission on Classification and Terminology of the International League against Epilepsy. 11 The patients (18 male and 12 female) were recruited randomly from those attending the outpatient clinic, Department of Research on Children with Special Needs, National Research Centre. Thirty clinically healthy children and adolescents with no history suggesting medical, neurological or psychiatric disorders were included as the control group. They were, both, age and sex matching the study group.
Exclusion criteria
Patients with lesional temporal lobe epilepsy, evidenced by MRI, and those with evidence of intercurrent infections or with other chronic illnesses known to affect apoptosis, e.g. autoimmune disorders, were excluded from the study.
Methods
All cases were subjected to full clinical neurological evaluation including:
Age at onset of seizures. Frequency of seizures (number of events per month) and duration of disease (in years). Type of seizure, whether partial or generalized according to International League Against Epilepsy (ILAE) classification. 11 Seizure severity according to The National Hospital Seizure Severity Scale. 12 Anti-epileptic drugs received. Control of seizures on therapy; patients were considered controlled if no seizure episodes occurred during the last 6 months. Presence of consanguinity and Family history of epilepsy including febrile seizures.
A standard interictal awake and sleep 16 channels digital EEG was performed for all cases, with a long-term EEG monitoring in selected cases to assure the temporal focus. Magnetic Resonance Imaging (MRI) study of the brain was done to all cases using epilepsy protocol. 13, 14 Neuropsychological assessment of cognitive function carried out using Wechsler intelligence scale for children. 15 
Serum Bcl-2 protein level analysis
Measurement of the serum level of Bcl-2 was carried out using a commercial enzyme linked immunosorbent assay technique (ELISA) following the manufacturer's instructions (Bender MedSystems GmbH, Austria). Blood was drawn from patients and healthy controls during routine follow up of school children. The samples were left to clot and sera were separated and stored at À70 8C until assay. Serum samples were assayed in duplicate. The absorbance of each microwell was read at 450 nm using ELISA reader STATFAX-2000. The concentration of Bcl-2 in a sample was determined by interpolation from a standard curve. The detection limit for Bcl-2 assay was 0.5 ng/ml, with the intra-assay coefficient of variation 8.6%.
Statistical methods
Data were analyzed using SPSS, computer package, version 17 (SPSS, Chicago, IL, USA). Data are presented as mean AE SD and median (interquartile range) for normally distributed and nonparametric data respectively. Student's t-test was used for comparison of normally distributed data between groups. Spearman's correlation coefficient was used to correlate various variables in the studied groups. Multivariate regression analysis was used to study correlation between multiple variables. For all tests p < 0.05 was considered to be statistically significant.
Results
Clinical parameters
The study included 30 patients with non-lesional TLE with a mean age of 10.03 AE 3.16 years and 30 controls matched for age and sex (Table 1) . Three (10%) were included within 6 months of diagnosis and only one patient (3.3%) after 36 months of diagnosis.
The mean age at onset of epilepsy in the patient group was 8.8 AE 3.3 years and the average duration of illness was 15.2 AE 6.9 months. Seizures, in eleven cases, were controlled while 19 were uncontrolled, with a median seizure frequency of one attack/month. The mean seizure severity scale was 10.5 AE 3.6 ( Table 1) .
The mean IQ was significantly lower in the patient group compared to the control group (Table 1) . IQ showed a significant inverse association with seizure severity and duration, but it did not correlate with either seizure frequency or age at onset of epilepsy (Table 2) . Multivariate regression analysis revealed that IQ was related to duration of epilepsy only (t = 3.2 and p < 0.001). 
Table 2
Correlation between IQ and seizure parameters of studied patients. 
Raised serum Bcl-2 in children with epilepsy
The serum levels of Bcl-2 were significantly higher (p < 0.001) in the patients (5.08 AE 1.05 ng) compared to the control group (2.27 AE 0.65 ng) (Fig. 1) . Within the patient group, serum Bcl-2 was significantly higher (p = 0.003) in uncontrolled patients (5.46 AE 1 ng) compared to controlled (4.42 AE 0.72 ng) patients (Table 3 ). Bcl-2 serum level was found to correlate positively with seizure variables including severity, frequency and duration (F = 11.61, 7.16, and 3.0 respectively) ( Table 4) . Multivariate regression analysis revealed correlation only to severity (t = 5.0, p < 0.001) and duration (t = 3.4, p = 0.02). Serum Bcl-2 levels were also found to be correlated negatively with total score IQ in the patient group (r = À0.62 and p < 0.001) (Fig. 2) .
Discussion
Recurrent seizures may pose a risk of injury to the brain. 2, 13 The mechanism of neuronal death after brief seizures is not fully understood but may involve activation of apoptosis-associated signaling pathways. 5, 6 Indeed, temporal lobe cortex and hippocampus from adults and children with refractory epilepsy show raised levels of both pro-and anti-apoptotic proteins, including Bcl-2. 6 In the present study we assayed serum Bcl-2 levels in children with TLE. We detected elevated Bcl-2 levels in epileptic patients and more elevated levels in patients with uncontrolled versus controlled seizures. Bcl-2 levels also correlated negatively with IQ. Taken together, these data suggest that epileptic seizures may influence expression of Bcl-2, either centrally or peripherally, and Bcl-2 may serve as a surrogate marker of apoptosis, caused by epileptic seizures, and their sequelae. Bcl-2 is an important anti-apoptotic protein which is upregulated in surviving cell populations following injury from ischemia, trauma, and seizures. 16 Several studies have reported increased
Bcl-2 levels in temporal lobe material from patients with epilepsy, including children. 6, 7 Bcl-2 up-regulation appears to be in neurons. 5 Whether this represents a protective adaptation is unknown although experimental delivery of Bcl-2 potently protects against neuronal apoptosis. 17 Thus, upregulation of Bcl-2 may be an adaptive response to seizure stress which contributes to limiting ongoing neuron loss. Experimental and human data suggest hippocampal damage in TLE is mainly a consequence of an initial precipitating injury. 18, 19 Nevertheless, evidence of a correlation between repeated brief seizures, brain damage, and the resulting cognitive deficit has been provided from animal models of TLE. Kotloski et al. 20 reported that cognitive deficits, after repeated seizures in rats, were in proportion to damage to the hippocampus. This study and other experimental and human data 21, 22 support the view that hippocampal sclerosis and associated memory dysfunction may be worsened by repeated seizures, and imply that seizure control could prevent adverse long-term consequences of seizures on hippocampal-dependent functions. Ten percent of cases were found to have positive family history of other affected members. Two, non related, patients have another affected sib. The other patient has two, affected, family members; his sib and a first cousin. They were, all, outcome of nonconsanguineous marriage up to the grandparents. Pedigree analysis of our cases pointed to a possible autosomal dominant trait. Absence of vertical transmission could be explained by reduced penetrance due to modifier genes and environmental interaction. 23 Two types of familial temporal lobe epilepsies (FTLE) were described based on seizure semiology, genetic background, and MRI characteristics namely the mesial (FMTLE) and the lateral (FLTLE) forms. 11 The finding of at least two TLE patients in one family is suggestive of FTLE. 24 An autosomal-dominant pattern of inheritance with incomplete penetrance, autosomal-recessive or sex linked inheritance cannot be ruled out in some families.
23,24
The first major finding in the present study was that serum Bcl-2 levels were elevated in children with epilepsy. Our study also found that Bcl-2 levels were higher in patients with poor seizure control compared to those where seizures were managed. Notably, serum Bcl-2 levels correlated positively with the severity and frequency of seizures as well as with the duration of epilepsy. On the other hand, Henshall et al. 25 reported that brain levels of the related Bcl-2 family protein, Bcl-xL correlated positively with seizure frequency, although Bcl-2 levels did not. Cherian et al., 26 also, reported extensive apoptosis in association with intractable status epilepticus in the resected brain specimen of an 8 1/2-month-old girl. This would be in agreement with experimental work that detected apoptosis-related proteins in the CSF following status epilepticus in rats Murphy et al. 27 Determining whether serum bcl-2 represents protein released as a result of tissue damage will be an important next step. We, also, know that Bcl-2 is not the only apoptosis-related protein which can be detected in serum in epilepsy. 14 Identification of other, potentially more sensitive serum proteins from among the apoptosis-related protein network will be valuable in extending the present work. Our findings compliment and extend previous work which investigated serum markers of apoptosis in children with epilepsy.
14 El-Hodhod et al. 14 reported an elevated serum levels of Bcl-2 in patients with idiopathic epilepsy and were related to the seizure severity and frequency. 14 As none of the patients in our study had lesional epilepsy, therefore, the raised serum Bcl-2 appears to be a consistent peripheral marker of epilepsy in children. The patient group in the El-Hodhod et al. 14 study was also less homogenous, comprising individuals with focal, focal with secondary generalization, and generalized seizures. Their patients were, also, on both mono-and polytherapy without specification. In contrast, our patient group represented a single epileptic syndrome on monotherapy (Carbamazepine).
A second important finding in the present study were the correlation between Bcl-2 serum level and total IQ score, in addition to seizure parameters. Thus, serum Bcl-2 levels were inversely correlated with IQ. The total IQ scores for patients were significantly lower than control and the predictive values were, namely, duration of epilepsy and severity of attacks. One interpretation of this data is that the longer the duration and the more severe the seizures the worse the negative impact on cognition. If serum Bcl-2 is a reliable biomarker of seizure activity then it may represent a novel means for tracking cognitive affects of seizures. Whether raised Bcl-2 levels in patient sera confer any protective effects on the brain is, currently, unknown. Our data are congruent with other findings on seizures and cognition in children. Stable aspects of cognitive function, such as IQ, are most closely related to the severity of the epilepsy syndrome (including average seizure frequency). 21 Thus seizures, which are known to have a direct transient effect on cognitive aspects, can affect stable cognitive aspects and the intelligence level. Desai 28 found that the most predictive parameters for cognitive impairment were age of onset, frequency of seizures, and duration of epilepsy. Our study was concordant with this as regards the duration of epilepsy being the strongest predictor. In addition there was a modest difference between IQ of controlled patients and patients with frequent seizures, although this did not reach significance (p = 0.09). Thus, epilepsy occurring in early childhood is frequently associated with considerable cognitive and behavioral morbidity. 29, 30 In summary, we found that serum Bcl-2 levels are elevated in children with TLE and is further increased in drug refractory patients. Although we do not know if it is derived directly from damaged CNS tissue or due to peripheral (e.g. immune) responses to seizures or other mechanisms, Bcl-2 could be a useful surrogate marker of progressive versus non-progressive epilepsy. Our study, also, highlights the potentially negative impact of seizures on cognitive function, supporting the need for better seizure management for children with TLE.
